Harold J. Burstein, MD, PhD, on Adjuvant Endocrine Therapy: Expert Perspective
2016 San Antonio Breast Cancer Symposium
Harold J. Burstein, MD, PhD, from Dana-Farber Cancer Institute, gives an update on the duration of adjuvant endocrine therapy and offers his expert views on putting the research data into clinical practice.
Monica Morrow, MD, of Memorial Sloan Kettering Cancer Center, recognized at this year’s meeting for scientific distinction in clinical research, summarizes her Brinker Award lecture on modifying local therapy to decrease the burden of cancer treatment.
Patricia A. Ganz, MD, of the UCLA Jonsson Comprehensive Cancer Center, summarizes two studies on using duloxetine for aromatase inhibitor–associated musculoskeletal symptoms, and aromatase inhibitors’ effect on endothelial function and heart disease (Abstracts S5-06 and S5-07).
Eric P. Winer, MD, of the Dana-Farber Cancer Institute, summarizes his McGuire lecture on the past and future of breast cancer treatment.
Matthew P. Goetz, MD, of the Mayo Clinic, reviews progress made during the past year on treatment of advanced disease.
Anne Hudson Blaes, MD, of the University of Minnesota, discusses the association between aromatase inhibitors, endothelial function, and early heart disease (Abstract S5-07).